Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonidine as adjunct to morphine for Neonatal Abstinence Syndrome
NCT03762317Phase 4Terminated
- Sponsor
- Hennepin Healthcare
- Start
- Apr 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Clonidine Lauriad in neonatal abstinence syndrome (NAS) (2 arms), sponsored by Hennepin Healthcare. Primary endpoint: Duration of Pharmacotherapy for Neonatal Abstinence Syndrome at 100 days. Started Apr 2018; status: terminated.
02
Drugs
Clonidine Lauriad
03
Conditions
neonatal abstinence syndrome (NAS)
Beyond the preview
Go deeper on NCT03762317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03762317.